Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MI136 是 menin-MLL(PPI) 蛋白互作的抑制剂,其 IC50值为31 nM,Kd 值为23.6 nM。它可抑制 DHT 诱导的雄激素受体 (AR) 靶基因的表达,有用于去势抵抗性肿瘤的潜能。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 368 | 现货 | ||
2 mg | ¥ 527 | 现货 | ||
5 mg | ¥ 872 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,960 | 现货 | ||
50 mg | ¥ 4,390 | 现货 | ||
100 mg | ¥ 6,280 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 962 | 现货 |
产品描述 | MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced. |
体外活性 | MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to MI-136. Treatment with MI-136 also inhibits the expression of genes that are bound to ASH2L after AR stimulation. Treatment with MI-136 induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage and blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of MI-136 on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer[1]. |
体内活性 | Treatment of VCaP tumor-bearing mice with MI-136 (40 mg/kg) leads to a modest but significant reduction in tumor volume with no effect on mouse body weight[1]. |
激酶实验 | HSP90 binding, ATPase, and selectivity profiling assays: The potency of HSP90 inhibitors for HSP90α, HSP90β, and Grp94 is determined by AlphaScreen competition binding assays, and activity against TRAP-1 is assessed by an ATPase assay. |
细胞实验 | To assess the effect of MI-136 on AR signaling, VCaP cells are treated with DMSO or 5 μM MI-136 for 48 hours. Cells are serum starved by replacing the media with DMEM containing 5% charcoal-striped serum and MI-136 for 48 hrs. Cells are then stimulated with 10 nM DHT for 12 hrs and RNA is isolated and processed for expression microarrays. (Only for Reference) |
分子量 | 470.51 |
分子式 | C23H21F3N6S |
CAS No. | 1628316-74-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 87 mg/mL (184.9 mM)
DMSO: 87 mg/mL (184.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1254 mL | 10.6268 mL | 21.2535 mL | 53.1338 mL |
5 mM | 0.4251 mL | 2.1254 mL | 4.2507 mL | 10.6268 mL | |
10 mM | 0.2125 mL | 1.0627 mL | 2.1254 mL | 5.3134 mL | |
20 mM | 0.1063 mL | 0.5313 mL | 1.0627 mL | 2.6567 mL | |
50 mM | 0.0425 mL | 0.2125 mL | 0.4251 mL | 1.0627 mL | |
100 mM | 0.0213 mL | 0.1063 mL | 0.2125 mL | 0.5313 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MI-136 1628316-74-4 Apoptosis Chromatin/Epigenetic Endocrinology/Hormones Epigenetic Reader Domain Androgen Receptor PPI inhibit MI 136 Inhibitor CRPC castration MI136 cancer resistant prostate inhibitor